Literature DB >> 21442078

Comparative clinical and airway inflammatory features of asthmatics with or without polyps.

Lara Bilodeau1, Marie-Eve Boulay, Philippe Prince, Pierre Boisvert, Louis-Philippe Boulet.   

Abstract

BACKGROUND: Nasal polyposis (NP) is associated with a more severe and steroid-resistant asthma.
OBJECTIVE: To compare clinical and airway inflammatory features of asthmatics with or without NP.
METHODS: Two groups of asthmatic patients were studied: group 1; n=39, with NP; group 2; n=40, without NP. Asthma control was assessed according to the Asthma Control Scoring System (ACSS). Expiratory flows, induced sputum, and blood eosinophils were also measured.
RESULTS: ACSS score was lower (poorer control) in group 1 (meanA+-SEM = 73A+-3%) compared with group 2 (82A+-2%, p=0.01). FEV1 (mean of predicted value A+- SEM) was 81A+-3 for group 1 and 96A+-3 for group 2 (p=0.001), and the FEV1/FVC ratio was lower in group 1 (70A+-2%) compared with group 2 (76A+-1%, p=0.01). Blood and induced sputum eosinophils, as well as fibronectin and eosinophil cationic protein levels, were higher in group 1.
CONCLUSION: Asthmatic subjects with NP have increased airway obstruction, increased inflammatory cells and reduced asthma control compared to those without NP. This may suggest a contribution of nasal polyps to the severity of asthma or a common susceptibility to develop upper and lower airways mucosal inflammation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21442078     DOI: 10.4193/Rhino09.095

Source DB:  PubMed          Journal:  Rhinology        ISSN: 0300-0729            Impact factor:   3.681


  8 in total

1.  Improvement in Health-Related Quality of Life with Dupilumab in Patients with Moderate-to-Severe Asthma with Comorbid Chronic Rhinosinusitis with/without Nasal Polyps: An Analysis of the QUEST Study.

Authors:  Claire Hopkins; Kathleen M Buchheit; Enrico Heffler; Noam A Cohen; Heidi Olze; Asif H Khan; Jérôme Msihid; Shahid Siddiqui; Scott Nash; Juby A Jacob-Nara; Paul J Rowe; Yamo Deniz
Journal:  J Asthma Allergy       Date:  2022-06-07

Review 2.  Damage-associated molecular patterns and their receptors in upper airway pathologies.

Authors:  Koen Van Crombruggen; Fenila Jacob; Nan Zhang; Claus Bachert
Journal:  Cell Mol Life Sci       Date:  2013-05-15       Impact factor: 9.261

Review 3.  Pathophysiology of chronic rhinosinusitis, pharmaceutical therapy options.

Authors:  Claus Bachert; Gabriële Holtappels
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2015-12-22

4.  Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma with and without Nasal Polyposis: A Post Hoc Analysis of the Phase 2b PATHWAY Study.

Authors:  Claire Emson; Jonathan Corren; Kinga Sałapa; Åsa Hellqvist; Jane R Parnes; Gene Colice
Journal:  J Asthma Allergy       Date:  2021-02-03

Review 5.  Type 2 inflammation in asthma and other airway diseases.

Authors:  Jorge Maspero; Yochai Adir; Mona Al-Ahmad; Carlos A Celis-Preciado; Federico D Colodenco; Pedro Giavina-Bianchi; Hani Lababidi; Olivier Ledanois; Bassam Mahoub; Diahn-Warng Perng; Juan C Vazquez; Arzu Yorgancioglu
Journal:  ERJ Open Res       Date:  2022-08-01

6.  Risk factors associated with comorbid asthma in patients with chronic rhinosinusitis with nasal polyps: a cross-sectional study.

Authors:  Fangyuan Li; Xuechen Wang; Jianmin Jin; Luo Zhang; Shen Shen; Kai Huang; Ming Wang; Xiaofang Liu; Chengshuo Wang
Journal:  BMC Pulm Med       Date:  2022-09-07       Impact factor: 3.320

Review 7.  Nasal polyps in patients with asthma: prevalence, impact, and management challenges.

Authors:  Cristobal Langdon; Joaquim Mullol
Journal:  J Asthma Allergy       Date:  2016-03-14

8.  Real-life effects of benralizumab on allergic chronic rhinosinusitis and nasal polyposis associated with severe asthma.

Authors:  Nicola Lombardo; Corrado Pelaia; Marco Ciriolo; Marcello Della Corte; Giovanna Piazzetta; Nadia Lobello; Pasquale Viola; Girolamo Pelaia
Journal:  Int J Immunopathol Pharmacol       Date:  2020 Jan-Dec       Impact factor: 3.219

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.